Canopy Growth (CGC) Receivables (2017 - 2026)
Canopy Growth (CGC) reported Receivables of $26.7 million for Q1 2026, down 19.81% on a YoY basis from $33.3 million in Q1 2025, and up 22.37% sequentially from $21.8 million in Q4 2025.
Canopy Growth (CGC) Receivables (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Receivables data on file, last reported at $26.7 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables fell 19.81% year-over-year to $26.7 million; the trailing twelve-month figure through Mar 2026 stood at $26.7 million (down 19.81% YoY), and the FY2026 full-year result was $26.7 million, down 27.78% from the prior year.
- Receivables rose to $26.7 million in Q1 2026, from $21.8 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $114.6 million in Q2 2023 to a low of $18.4 million in Q3 2025.
- A 5-year average of $47.0 million and a median of $41.1 million in 2024 frame the typical range for Receivables.
- Across the five-year window, Receivables soared 66.56% in 2023 and tumbled 70.47% in 2024, its largest moves.
- Tracing CGC's Receivables over 5 years: stood at $62.1 million in 2022, then fell by 17.49% to $51.2 million in 2023, then plunged by 30.04% to $35.8 million in 2024, then plunged by 39.18% to $21.8 million in 2025, then climbed by 22.37% to $26.7 million in 2026.
- Business Quant data shows CGC's Receivables at $26.7 million in Q1 2026, $21.8 million in Q4 2025, and $18.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 26.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.67 Mn |
| Dec 31, 2025 | 21.80 Mn |
| Sep 30, 2025 | 18.39 Mn |
| Jun 30, 2025 | 36.34 Mn |
| Mar 31, 2025 | 33.27 Mn |
| Dec 31, 2024 | 35.84 Mn |
| Sep 30, 2024 | 28.51 Mn |
| Jun 30, 2024 | 33.85 Mn |
| Mar 31, 2024 | 41.08 Mn |
| Dec 31, 2023 | 51.22 Mn |
| Sep 30, 2023 | 41.76 Mn |
| Jun 30, 2023 | 114.62 Mn |
| Mar 31, 2023 | 59.26 Mn |
| Dec 31, 2022 | 62.08 Mn |
| Sep 30, 2022 | 66.78 Mn |
| Jun 30, 2022 | 68.82 Mn |
| Mar 31, 2022 | 58.94 Mn |
| Dec 31, 2021 | 70.59 Mn |
| Sep 30, 2021 | 64.04 Mn |
| Jun 30, 2021 | 91.53 Mn |